FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The drug received standard U.S. approval in 2023 after showing it slowed cognitive decline in patients with the brain-wasting ...